Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 9/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 8/20 | 1.00 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 1.00 |
| ▸ | LPAR4 | Q99677 | 3/20 | 1.00 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 1.00 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 1.00 |
| ▸ | LPAR6 | P43657 | 2/20 | 1.00 |
| ▸ | CES2 | O00748 | 1/20 | 0.85 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | P2RY10 | O00398 | 3/20 | 0.68 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.68 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.68 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6362553 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 | |
| SCHEMBL8508094 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 | |
| SCHEMBL13043253 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 | |
| SCHEMBL2936577 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 | |
| SCHEMBL8508530 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 | |
| SCHEMBL8509455 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 | |
| SCHEMBL8736955 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 | |
| SCHEMBL8509038 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 | |
| SCHEMBL2935665 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 | |
| SCHEMBL8507661 | 1.00 | LPAR1 (1.00) | LPAR1ENPP2LPAR3LPAR4LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110044990-A1 | ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES | LPATH, INC. | 2011-02-24 | — | — | US | disclosed |
| US-7862812-B2 | Methods for decreasing immune response and treating immune conditions | LPATH, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-20090220523-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC, INFLAMMATORY AND NEOVASCULARIZATION CONDITIONS | LPATH INC. | 2009-09-03 | — | — | US | disclosed |
| US-20070280933-A1 | Methods for decreasing immune response and treating immune conditions | APOLLO ENDOSURGERY, INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070280933-A1 | Methods for decreasing immune response and treating immune conditions | LPAR1, LPAR2, S1PR1 | LPAR1 1/4885ENPP2 19/4885LPAR3 10/4885 |
| US-20110044990-A1 | ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES | S1PR5, S1PR4, S1PR2 | LPAR1 36/4885ENPP2 83/4885LPAR3 27/4885 |
| US-20090220523-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC, INFLAMMATORY AND NEOVASCULARIZATION CONDITIONS | S1PR5, S1PR3, S1PR1 | LPAR1 10/4885ENPP2 19/4885LPAR3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.